ArticleThoracic cancer2023

Refractory response to entrectinib for ROS-1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report.

Kentaro Ito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.